What this is
- How it works
- Sphingosine 1-phosphate Receptor Modulator FDA class
- How it’s given
- “Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).”In the company’s words, NCT04926818 on ClinicalTrials.gov
- Tested for
- Multiple Sclerosis (MS)
- Main trialPhase 3
- “Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis”In the company’s words, NCT04926818 on ClinicalTrials.gov
- Other names
- BAF312
Other drugs for Multiple Sclerosis (MS)
- IMU-838Immunic AG · Phase 3
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- FrexalimabSanofi · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- PrivosegtorOculis · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 25 Mar 2026 | Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis | |
| Phase 4Completed | 6 Sep 2021 | Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) | |
| Phase 3Completed | 29 Apr 2016 | Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) | |
| Phase 3Completed | 6 Jul 2022 | Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients | |
| Phase 2Terminated | 17 Feb 2016 | Safety and Efficacy of BAF312 in Dermatomyositis | |
| Phase 2Terminated | 5 Aug 2016 | Efficacy and Tolerability of BAF312 in Patients With Polymyositis | |
| Phase 2Completed | 13 May 2020 | Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). | |
| Phase 4Authorised | not given | Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis | |
| Phase 4Authorised | not given | Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026